Authors: Iversen, LF Andersen, HS Moller, KB Olsen, OH Peters, GH Branner, S Mortensen, SB Hansen, TK Lau, J Ge, Y Holsworth, DD Newman, NJ Moller, NPH

Citation: Lf. Iversen et al., Steric hindrance as a basis for structure-based design of selective inhibitors of protein-tyrosine phosphatases, BIOCHEM, 40(49), 2001, pp. 14812-14820

Authors: Oturai, PS Christensen, M Rolin, B Pedersen, KE Mortensen, SB Boel, E

Citation: Ps. Oturai et al., Effects of advanced glycation end-product inhibition and cross-link breakage in diabetic rats, METABOLISM, 49(8), 2000, pp. 996-1000

Authors: Peters, GH Iversen, LF Branner, S Andersen, HS Mortensen, SB Olsen, OH Moller, KB Moller, NPH

Citation: Gh. Peters et al., Residue 259 is a key determinant of substrate specificity of protein-tyrosine phosphatases 1B and alpha, J BIOL CHEM, 275(24), 2000, pp. 18201-18209

Authors: Iversen, LF Andersen, HS Branner, S Mortensen, SB Peters, GH Norris, K Olsen, OH Jeppesen, CB Lundt, BF Ripka, W Moller, KB Moller, NPH

Citation: Lf. Iversen et al., Structure-based design of a low molecular weight, nonphosphorus, nonpeptide, and highly selective inhibitor of protein-tyrosine phosphatase 1B, J BIOL CHEM, 275(14), 2000, pp. 10300-10307

Authors: Soulis, T Sastra, S Thallas, V Mortensen, SB Wilken, M Clausen, JT Bjerrum, OJ Petersen, H Lau, J Jerums, G Boel, E Cooper, ME

Citation: T. Soulis et al., A novel inhibitor of advanced glycation end-product formation inhibits mesenteric vascular hypertrophy in experimental diabetes, DIABETOLOG, 42(4), 1999, pp. 472-479